Clinical trials: Adverse Drug Interaction
Ranitidine Adverse Reaction, Pharmacokinetics
Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration
Ranitidine is an over-the-counter and prescription drug, which decreases the amount of acid secreted by the stomach. Some ranitidine medicines contain an impurity called N-nitrosodimethylamine (NDMA) at low levels.
- Conditions
- Ranitidine Adverse Reaction, Pharmacokinetics, Food-drug Interaction
- Trial name
- NCT04397445
- Testing
- Ranitidine, Low nitrite/NDMA meals, High nitrite/NDMA meals
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)
Adverse Drug Interactions
Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions
Adverse drug-drug interactions (DDIs) are responsible for approximately 3% of all hospitalizations in the US, perhaps costing more than $1.3 billion per year.
- Trial name
- NCT00621309
- Testing
- Rifampicin, sulforaphane plus rifampicin, sulforaphane alone
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Washington
Latent Tuberculosis, Human Immunodeficiency Virus
Doravirine, Rifapentine and Isoniazid Interaction
Drug therapy for persons living with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) co-infected with latent tuberculosis infection (LTBI) is complex.
- Conditions
- Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use, Drug Interaction Potentiation
- Trial name
- DORIIS (NCT03886701)
- Testing
- Doravirine (DOR), Rifapentine (RPT), Isoniazid (INH)
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Walter K. Kraft
Adverse Drug Events, Adverse Drug Reactions
Pharmacogenetic Testing Among Home Health Patients
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing.
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- NCT02378220
- Testing
- Pharmacogenetic testing
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Genelex Corporation
Interaction, Adverse Herb-Drug, Diabetes Mellitus, Type 2
Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients
Supplements containing goldenseal, a perennial herb native to North America, have consistently ranked among the top 20 highest selling natural products throughout the last decade.
- Trial name
- NCT05081583
- Testing
- Midazolam Hcl 1Mg/Ml Inj, Goldenseal (Hydrastis canadensis)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Washington State University
Pharmacogenetic Testing
Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population
Use of polypharmacy has significantly increased over the past two decades, which has unproven clinical benefit and is associate with an increased the risk of adverse side effects.
- Trial name
- MedOPT (NCT03468309)
- Testing
- Genecept Assay and G-DIG decision tool
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Parent-Child Relations, Maternal Behavior
A Randomized Controlled Trial to Improve Mother-Infant Synchrony Among Women With Childhood Adversity
Childhood adversity affects almost two-thirds of the US population, is a major risk factor for the leading causes of disease and increases US economic health burdens.
- Conditions
- Parent-Child Relations, Maternal Behavior, Infant Behavior
- Trial name
- NCT04818112
- Testing
- ATVV, Attention control
- Where
- 2 sites in United States
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Drug Toxicity
Regional Data Exchange to Improve Medication Safety
Medication reconciliation, a process by which a provider obtains and documents a thorough medication history with specific attention to comparing current and previous medication use, can prevent medication-related errors and…
- Trial name
- NCT01239121
- Testing
- HIE-Enhanced Medication Reconciliation, Optimal Medication Reconciliation without HIE
- Where
- United States
- Volunteers
- 402 people
- Sponsor
- VA Office of Research and Development
Pain, Postoperative, Medication Adherence
Evaluation of an Interactive Opioid Risk Education Program (STOMP) for Parents
Millions of children and adolescents are prescribed opioid pain relievers each year, placing them at risk for serious adverse events and misuse in the home setting.
- Conditions
- Pain, Postoperative, Medication Adherence, Opioid Use, Knowledge, Attitudes, Practice
- Trial name
- STOMP (NCT03287622)
- Testing
- Educational Intervention, Nudge
- Where
- United States
- Volunteers
- 712 people
- Sponsor
- University of Michigan
Cannabidiol, Drug Induced Liver Injury
Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
Cannabidiol (CBD) is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
- Conditions
- Cannabidiol, Drug Induced Liver Injury, Drug Interaction
- Trial name
- NCT06192589
- Testing
- Cannabidiol, Citalopram, Morphine
- Where
- United States
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)